News & Updates

Evidence on the association of weak opioids with a higher risk of oesophageal and colorectal cancer is not reliable, but there appears to be a small association with gastric cancer, suggests a study.

Novel systemic treatments are similarly effective in reducing the risk of progression or death in patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC), irrespective of visceral metastasis status, reports a study.

A dexamethasone-free regimen helps improve control of nausea and vomiting in patients receiving “highly emetogenic” chemotherapy, with the antiemetic effect being superior to that of a dexamethasone-based regimen, according to the results of a phase III trial presented at ASCO Breakthrough 2023.

In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.

A single dose of esketamine appears to enhance the efficacy of oral antidepressants for treating patients with major depressive disorder (MDD) who are experiencing fluctuating symptoms, as reported in a small study.